This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.
Study Type
OBSERVATIONAL
Enrollment
20
Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.
Lei Li
Beijing, Beijing Municipality, China
RECRUITINGObjective remission rate
Objective remission rate in one month after the end of radiotherapy
Time frame: One year
Progression-free survival
Progression-free survival after the end of radiotherapy
Time frame: One year
Overall survival
Overall survival after the end of radiotherapy
Time frame: One year
Severe adverse events
Severe adverse events during the radiotherapy and the follow-up stage
Time frame: Two years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.